JAZZ Jazz Pharmaceuticals plc
Stock · NasdaqGS · Ireland · Healthcare · IE00B4Q5ZN47
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Jazz Pharmaceuticals plc, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
234.76 USD
+3.27%
52-week range
128.80 – 266.38
Dividend yield—
Market cap14.6B
NowoTrade score
38 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:10. Information, not advice.
Results
Next results
23 Feb 2027
in 108 days · 16:00 · estimate 6.64
Last results
-3.88 vs -2.38 estimated
02 Nov 2026 · Miss -63.4%
Beat the estimate
6 of 12
6 missed · 0 in line
Average surprise
-7.0%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 23 Feb 2027 16:00 | 6.64 | — | — | Upcoming |
| 02 Nov 2026 16:00 | -2.38 | -3.88 | -63.4% | Miss |
| 03 Aug 2026 16:00 | 6.18 | 5.71 | -7.5% | Miss |
| 05 May 2026 16:00 | 4.66 | 6.34 | +36.2% | Beat |
| 24 Feb 2026 16:00 | 6.51 | 6.64 | +2.1% | Beat |
| 05 Nov 2025 16:00 | 5.85 | 8.13 | +39.0% | Beat |
| 05 Aug 2025 16:00 | -6.25 | -8.25 | -32.1% | Miss |
| 06 May 2025 16:00 | 4.66 | 1.68 | -63.9% | Miss |
| 25 Feb 2025 16:00 | 5.81 | 6.60 | +13.6% | Beat |
| 06 Nov 2024 16:00 | 5.50 | 6.61 | +20.2% | Beat |
| 31 Jul 2024 16:00 | 4.78 | 5.30 | +10.8% | Beat |
| 01 May 2024 16:00 | 4.18 | 2.68 | -35.9% | Miss |
| 28 Feb 2024 16:00 | 5.18 | 5.02 | -3.2% | Miss |
| 08 Nov 2023 16:00 | 4.93 | 4.84 | -1.9% | Miss |
| 09 Aug 2023 16:00 | 4.43 | 4.51 | +1.8% | Beat |
| 10 May 2023 16:00 | 4.22 | 3.95 | -6.4% | Miss |
| 01 Mar 2023 16:00 | 1.12 | -0.07 | -106.3% | Miss |
| 09 Nov 2022 16:00 | 4.67 | 5.17 | +10.6% | Beat |
| 03 Aug 2022 16:00 | 4.19 | 4.30 | +2.5% | Beat |
| 04 May 2022 16:00 | 3.89 | 3.73 | -4.1% | Miss |
| 01 Mar 2022 16:00 | 3.64 | 4.21 | +15.6% | Beat |
| 09 Nov 2021 16:00 | 3.31 | 4.20 | +26.7% | Beat |
| 03 Aug 2021 16:00 | 3.45 | 3.90 | +13.2% | Beat |
| 04 May 2021 16:00 | 3.73 | 3.92 | +5.0% | Beat |
| 23 Feb 2021 16:00 | 4.20 | 4.00 | -4.8% | Miss |
| 02 Nov 2020 16:00 | 4.08 | 4.31 | +5.7% | Beat |
| 04 Aug 2020 16:00 | 3.11 | 3.71 | +19.2% | Beat |
| 05 May 2020 17:00 | 0.67 | 0.45 | -33.0% | Miss |
| 25 Feb 2020 16:00 | 4.12 | 4.42 | +7.3% | Beat |
| 05 Nov 2019 16:00 | 3.59 | 4.10 | +14.1% | Beat |
| 06 Aug 2019 16:00 | 3.57 | 4.05 | +13.4% | Beat |
| 07 May 2019 16:00 | 3.16 | 3.67 | +16.2% | Beat |
| 26 Feb 2019 16:00 | 3.03 | 3.64 | +20.2% | Beat |
| 06 Nov 2018 16:00 | 3.32 | 3.58 | +7.8% | Beat |
| 07 Aug 2018 16:00 | 3.21 | 3.49 | +8.8% | Beat |
| 08 May 2018 16:00 | 2.78 | 2.98 | +7.2% | Beat |
| 27 Feb 2018 16:00 | 2.96 | 2.95 | -0.4% | In line |
| 07 Nov 2017 16:00 | 2.89 | 3.22 | +11.5% | Beat |
| 08 Aug 2017 16:00 | 2.75 | 2.56 | -6.9% | Miss |
| 09 May 2017 16:00 | 2.34 | 2.31 | -1.3% | Miss |
| 28 Feb 2017 16:00 | 2.65 | 2.71 | +2.1% | Beat |
| 08 Nov 2016 16:00 | 2.61 | 2.57 | -1.5% | Miss |
| 09 Aug 2016 16:00 | 2.81 | 2.63 | -6.3% | Miss |
| 10 May 2016 16:00 | 2.32 | 2.26 | -2.7% | Miss |
| 23 Feb 2016 16:00 | 2.60 | 2.60 | +0.1% | In line |
| 09 Nov 2015 16:00 | 2.56 | 2.52 | -1.4% | Miss |
| 05 Aug 2015 16:00 | 2.41 | 2.41 | -0.2% | In line |
| 07 May 2015 16:00 | 2.15 | 1.99 | -7.6% | Miss |
| 24 Feb 2015 16:00 | 2.30 | 2.44 | +5.9% | Beat |
| 04 Nov 2014 16:00 | 2.21 | 2.33 | +5.5% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 4.3B | +4.9% | -356.1M | -8.3% | -5.84 | -167.5% | 1.1B |
| 2024 | 4.1B | +6.1% | 560.1M | 13.8% | 8.65 | +41.8% | 1.3B |
| 2023 | 3.8B | +4.8% | 414.8M | 10.8% | 6.10 | +270.4% | 1B |
| 2022 | 3.7B | — | -224.1M | -6.1% | -3.58 | — | 773.8M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 05 Apr 2024 | 115.19 | 116.86 | 114.82 | 116.42 | +1.05% | 530,800 | |
| 04 Apr 2024 | 117.56 | 118.01 | 115.10 | 115.21 | -1.46% | 512,000 | |
| 03 Apr 2024 | 117.55 | 117.98 | 116.23 | 116.92 | -0.54% | 425,700 | |
| 02 Apr 2024 | 118.51 | 119.42 | 117.05 | 117.55 | -1.20% | 571,300 | |
| 01 Apr 2024 | 120.58 | 120.81 | 118.21 | 118.98 | -1.20% | 360,300 | |
| 28 Mar 2024 | 120.51 | 121.53 | 120.03 | 120.42 | -0.07% | 409,900 | |
| 27 Mar 2024 | 118.58 | 120.55 | 118.15 | 120.51 | +2.19% | 471,600 | |
| 26 Mar 2024 | 120.60 | 120.86 | 117.71 | 117.93 | -2.37% | 1,689,800 | |
| 25 Mar 2024 | 122.33 | 123.68 | 120.60 | 120.79 | -0.84% | 597,500 | |
| 22 Mar 2024 | 124.62 | 125.27 | 121.51 | 121.81 | -1.85% | 691,800 | |
| 21 Mar 2024 | 125.31 | 125.95 | 123.63 | 124.10 | -0.55% | 682,900 | |
| 20 Mar 2024 | 124.01 | 125.65 | 123.41 | 124.79 | -0.17% | 675,500 | |
| 19 Mar 2024 | 123.49 | 125.28 | 123.08 | 125.00 | +1.29% | 803,600 | |
| 18 Mar 2024 | 120.42 | 123.93 | 120.42 | 123.41 | +2.08% | 841,700 | |
| 15 Mar 2024 | 118.13 | 121.59 | 118.13 | 120.90 | +2.20% | 1,529,400 | |
| 14 Mar 2024 | 117.50 | 118.36 | 116.57 | 118.30 | +0.45% | 606,300 | |
| 13 Mar 2024 | 115.80 | 118.20 | 115.80 | 117.77 | +1.71% | 458,700 | |
| 12 Mar 2024 | 116.12 | 116.81 | 115.45 | 115.79 | -0.72% | 492,400 | |
| 11 Mar 2024 | 117.01 | 118.81 | 116.60 | 116.63 | -0.77% | 456,000 | |
| 08 Mar 2024 | 116.36 | 119.04 | 116.02 | 117.53 | +1.00% | 420,700 | |
| 07 Mar 2024 | 117.05 | 117.54 | 115.68 | 116.37 | -0.70% | 593,600 | |
| 06 Mar 2024 | 120.85 | 122.11 | 116.82 | 117.19 | -1.04% | 734,600 | |
| 05 Mar 2024 | 117.40 | 119.50 | 116.67 | 118.42 | +0.76% | 782,300 | |
| 04 Mar 2024 | 119.06 | 120.00 | 115.64 | 117.53 | -1.11% | 1,098,800 | |
| 01 Mar 2024 | 119.65 | 122.57 | 118.54 | 118.85 | -0.04% | 1,044,400 |
Page 27 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Jazz Pharmaceuticals (JAZZ) Stock Jumps On Q2 Earnings Turnaround (opens in a new tab) Simply Wall St. · 03 Nov 2026 22:20
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (opens in a new tab) 03 Nov 2026 21:15
- Jazz Pharmaceuticals PLC (JAZZ) (Q3 2026) Earnings Call Highlights: Record $1. ... (opens in a new tab) GuruFocus.com · 03 Nov 2026 21:02
- JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View (opens in a new tab) Zacks · 03 Nov 2026 15:12
- JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310 (opens in a new tab) Benzinga · 03 Nov 2026 14:03
- Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319 (opens in a new tab) Benzinga · 03 Nov 2026 13:36
- Jazz Pharmaceuticals plc Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 03 Nov 2026 13:30
- RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305 (opens in a new tab) Benzinga · 03 Nov 2026 11:01
- Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275 (opens in a new tab) Benzinga · 03 Nov 2026 10:48
- Jazz: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 03 Nov 2026 04:29
- Jazz (JAZZ) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 04:28
- Jazz Pharmaceuticals (JAZZ) Will Present Phase 3 And Phase 2 Brain Cancer Data (opens in a new tab) Simply Wall St. · 03 Nov 2026 03:21
- Jazz Pharmaceuticals (JAZZ) Could Be 27% Undervalued As Record Revenue Lifts Outlook (opens in a new tab) Simply Wall St. · 03 Nov 2026 02:15
- Jazz Pharmaceuticals (JAZZ) Stock Could Be Undervalued On Ziihera Launch News (opens in a new tab) Simply Wall St. · 03 Nov 2026 01:22
- Jazz Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 03 Nov 2026 01:14
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 227.32 USD
- Market cap
- 14.6B
- Exchange
- NasdaqGS
- Country
- Ireland
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 1.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 14.5 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 69.46× | Weak | 31.09× |
| P/E (forward) | 9.03× | Good | 14.98× |
| Price / book | 3.59× | Weak | 3.87× |
| Price / sales | 3.19× | Fair | 3.42× |
| EV / EBITDA | 8.64× | Good | 13.09× |
| Free cash flow yield | 11.2% | Good | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 91.1% | Good | 59.2% |
| Operating margin | 30.2% | Good | 7.8% |
| Net margin | 4.4% | Weak | 3.4% |
| Return on equity | 5.1% | Weak | 5.7% |
| Return on assets | 6.9% | Fair | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 5.3% | Fair | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.35× | Fair | 0.46× |
| Net debt / EBITDA | 1.39× | Good | 1.48× |
| Interest cover | 2.65× | Weak | 3.26× |
| Current ratio | 1.82× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow JAZZ and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.